Breast Cancer Diagnostics Market Size, Share Report by 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Breast Cancer Diagnostics Market Size Analysis

Global Breast Cancer Diagnostics Market Introduction
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Invasive lobular breast cancer
  1. By Value
3. Ductal carcinoma in situ (DCIS)
  1. By Value
4. Triple-negative breast cancer
  1. By Value
5. Inflammatory breast cancer
  1. By Value
6. Others
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Clinical Breast Exam
  1. By Value
3. Blood Tests
  1. By Value
4. Imaging Tests
  1. By Value
  2. Mammogram
    1. Mammogram By Value
  3. MRI
    1. MRI By Value
  4. Ultrasound
    1. Ultrasound By Value
  5. PET
    1. PET By Value
  6. Others
    1. Others By Value
5. Biopsies
  1. By Value
  2. Excisional biopsy
    1. Excisional biopsy By Value
  3. Incisional biopsy
    1. Incisional biopsy By Value
  4. Core biopsy
    1. Core biopsy By Value
  5. Fine-needle aspiration (FNA) biopsy
    1. Fine-needle aspiration (FNA) biopsy By Value
  6. Others
    1. Others By Value
6. Others
  1. By Value
By Stage
1. Introduction
  1. Stage By Value
2. Stage I
  1. By Value
3. Stage II
  1. By Value
4. Stage III
  1. By Value
5. Stage IV
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Cancer Diagnostic Centers
  1. By Value
4. Cancer Research Institutes
  1. By Value
5. Ambulatory Surgical Centers
  1. By Value
6. Others
  1. By Value

North America Market Analysis

Introduction
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Invasive lobular breast cancer
  1. By Value
3. Ductal carcinoma in situ (DCIS)
  1. By Value
4. Triple-negative breast cancer
  1. By Value
5. Inflammatory breast cancer
  1. By Value
6. Others
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Clinical Breast Exam
  1. By Value
3. Blood Tests
  1. By Value
4. Imaging Tests
  1. By Value
  2. Mammogram
    1. Mammogram By Value
  3. MRI
    1. MRI By Value
  4. Ultrasound
    1. Ultrasound By Value
  5. PET
    1. PET By Value
  6. Others
    1. Others By Value
5. Biopsies
  1. By Value
  2. Excisional biopsy
    1. Excisional biopsy By Value
  3. Incisional biopsy
    1. Incisional biopsy By Value
  4. Core biopsy
    1. Core biopsy By Value
  5. Fine-needle aspiration (FNA) biopsy
    1. Fine-needle aspiration (FNA) biopsy By Value
  6. Others
    1. Others By Value
6. Others
  1. By Value
By Stage
1. Introduction
  1. Stage By Value
2. Stage I
  1. By Value
3. Stage II
  1. By Value
4. Stage III
  1. By Value
5. Stage IV
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Cancer Diagnostic Centers
  1. By Value
4. Cancer Research Institutes
  1. By Value
5. Ambulatory Surgical Centers
  1. By Value
6. Others
  1. By Value
U.S.
1. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Invasive lobular breast cancer
    1. By Value
  3. Ductal carcinoma in situ (DCIS)
    1. By Value
  4. Triple-negative breast cancer
    1. By Value
  5. Inflammatory breast cancer
    1. By Value
  6. Others
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Clinical Breast Exam
    1. By Value
  3. Blood Tests
    1. By Value
  4. Imaging Tests
    1. By Value
    2. Mammogram
      1. Mammogram By Value
    3. MRI
      1. MRI By Value
    4. Ultrasound
      1. Ultrasound By Value
    5. PET
      1. PET By Value
    6. Others
      1. Others By Value
  5. Biopsies
    1. By Value
    2. Excisional biopsy
      1. Excisional biopsy By Value
    3. Incisional biopsy
      1. Incisional biopsy By Value
    4. Core biopsy
      1. Core biopsy By Value
    5. Fine-needle aspiration (FNA) biopsy
      1. Fine-needle aspiration (FNA) biopsy By Value
    6. Others
      1. Others By Value
  6. Others
    1. By Value
3. By Stage
  1. Introduction
    1. Stage By Value
  2. Stage I
    1. By Value
  3. Stage II
    1. By Value
  4. Stage III
    1. By Value
  5. Stage IV
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Cancer Diagnostic Centers
    1. By Value
  4. Cancer Research Institutes
    1. By Value
  5. Ambulatory Surgical Centers
    1. By Value
  6. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Invasive lobular breast cancer
  1. By Value
3. Ductal carcinoma in situ (DCIS)
  1. By Value
4. Triple-negative breast cancer
  1. By Value
5. Inflammatory breast cancer
  1. By Value
6. Others
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Clinical Breast Exam
  1. By Value
3. Blood Tests
  1. By Value
4. Imaging Tests
  1. By Value
  2. Mammogram
    1. Mammogram By Value
  3. MRI
    1. MRI By Value
  4. Ultrasound
    1. Ultrasound By Value
  5. PET
    1. PET By Value
  6. Others
    1. Others By Value
5. Biopsies
  1. By Value
  2. Excisional biopsy
    1. Excisional biopsy By Value
  3. Incisional biopsy
    1. Incisional biopsy By Value
  4. Core biopsy
    1. Core biopsy By Value
  5. Fine-needle aspiration (FNA) biopsy
    1. Fine-needle aspiration (FNA) biopsy By Value
  6. Others
    1. Others By Value
6. Others
  1. By Value
By Stage
1. Introduction
  1. Stage By Value
2. Stage I
  1. By Value
3. Stage II
  1. By Value
4. Stage III
  1. By Value
5. Stage IV
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Cancer Diagnostic Centers
  1. By Value
4. Cancer Research Institutes
  1. By Value
5. Ambulatory Surgical Centers
  1. By Value
6. Others
  1. By Value
U.K.
1. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Invasive lobular breast cancer
    1. By Value
  3. Ductal carcinoma in situ (DCIS)
    1. By Value
  4. Triple-negative breast cancer
    1. By Value
  5. Inflammatory breast cancer
    1. By Value
  6. Others
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Clinical Breast Exam
    1. By Value
  3. Blood Tests
    1. By Value
  4. Imaging Tests
    1. By Value
    2. Mammogram
      1. Mammogram By Value
    3. MRI
      1. MRI By Value
    4. Ultrasound
      1. Ultrasound By Value
    5. PET
      1. PET By Value
    6. Others
      1. Others By Value
  5. Biopsies
    1. By Value
    2. Excisional biopsy
      1. Excisional biopsy By Value
    3. Incisional biopsy
      1. Incisional biopsy By Value
    4. Core biopsy
      1. Core biopsy By Value
    5. Fine-needle aspiration (FNA) biopsy
      1. Fine-needle aspiration (FNA) biopsy By Value
    6. Others
      1. Others By Value
  6. Others
    1. By Value
3. By Stage
  1. Introduction
    1. Stage By Value
  2. Stage I
    1. By Value
  3. Stage II
    1. By Value
  4. Stage III
    1. By Value
  5. Stage IV
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Cancer Diagnostic Centers
    1. By Value
  4. Cancer Research Institutes
    1. By Value
  5. Ambulatory Surgical Centers
    1. By Value
  6. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Invasive lobular breast cancer
  1. By Value
3. Ductal carcinoma in situ (DCIS)
  1. By Value
4. Triple-negative breast cancer
  1. By Value
5. Inflammatory breast cancer
  1. By Value
6. Others
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Clinical Breast Exam
  1. By Value
3. Blood Tests
  1. By Value
4. Imaging Tests
  1. By Value
  2. Mammogram
    1. Mammogram By Value
  3. MRI
    1. MRI By Value
  4. Ultrasound
    1. Ultrasound By Value
  5. PET
    1. PET By Value
  6. Others
    1. Others By Value
5. Biopsies
  1. By Value
  2. Excisional biopsy
    1. Excisional biopsy By Value
  3. Incisional biopsy
    1. Incisional biopsy By Value
  4. Core biopsy
    1. Core biopsy By Value
  5. Fine-needle aspiration (FNA) biopsy
    1. Fine-needle aspiration (FNA) biopsy By Value
  6. Others
    1. Others By Value
6. Others
  1. By Value
By Stage
1. Introduction
  1. Stage By Value
2. Stage I
  1. By Value
3. Stage II
  1. By Value
4. Stage III
  1. By Value
5. Stage IV
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Cancer Diagnostic Centers
  1. By Value
4. Cancer Research Institutes
  1. By Value
5. Ambulatory Surgical Centers
  1. By Value
6. Others
  1. By Value
China
1. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Invasive lobular breast cancer
    1. By Value
  3. Ductal carcinoma in situ (DCIS)
    1. By Value
  4. Triple-negative breast cancer
    1. By Value
  5. Inflammatory breast cancer
    1. By Value
  6. Others
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Clinical Breast Exam
    1. By Value
  3. Blood Tests
    1. By Value
  4. Imaging Tests
    1. By Value
    2. Mammogram
      1. Mammogram By Value
    3. MRI
      1. MRI By Value
    4. Ultrasound
      1. Ultrasound By Value
    5. PET
      1. PET By Value
    6. Others
      1. Others By Value
  5. Biopsies
    1. By Value
    2. Excisional biopsy
      1. Excisional biopsy By Value
    3. Incisional biopsy
      1. Incisional biopsy By Value
    4. Core biopsy
      1. Core biopsy By Value
    5. Fine-needle aspiration (FNA) biopsy
      1. Fine-needle aspiration (FNA) biopsy By Value
    6. Others
      1. Others By Value
  6. Others
    1. By Value
3. By Stage
  1. Introduction
    1. Stage By Value
  2. Stage I
    1. By Value
  3. Stage II
    1. By Value
  4. Stage III
    1. By Value
  5. Stage IV
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Cancer Diagnostic Centers
    1. By Value
  4. Cancer Research Institutes
    1. By Value
  5. Ambulatory Surgical Centers
    1. By Value
  6. Others
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Invasive lobular breast cancer
  1. By Value
3. Ductal carcinoma in situ (DCIS)
  1. By Value
4. Triple-negative breast cancer
  1. By Value
5. Inflammatory breast cancer
  1. By Value
6. Others
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Clinical Breast Exam
  1. By Value
3. Blood Tests
  1. By Value
4. Imaging Tests
  1. By Value
  2. Mammogram
    1. Mammogram By Value
  3. MRI
    1. MRI By Value
  4. Ultrasound
    1. Ultrasound By Value
  5. PET
    1. PET By Value
  6. Others
    1. Others By Value
5. Biopsies
  1. By Value
  2. Excisional biopsy
    1. Excisional biopsy By Value
  3. Incisional biopsy
    1. Incisional biopsy By Value
  4. Core biopsy
    1. Core biopsy By Value
  5. Fine-needle aspiration (FNA) biopsy
    1. Fine-needle aspiration (FNA) biopsy By Value
  6. Others
    1. Others By Value
6. Others
  1. By Value
By Stage
1. Introduction
  1. Stage By Value
2. Stage I
  1. By Value
3. Stage II
  1. By Value
4. Stage III
  1. By Value
5. Stage IV
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Cancer Diagnostic Centers
  1. By Value
4. Cancer Research Institutes
  1. By Value
5. Ambulatory Surgical Centers
  1. By Value
6. Others
  1. By Value
UAE
1. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Invasive lobular breast cancer
    1. By Value
  3. Ductal carcinoma in situ (DCIS)
    1. By Value
  4. Triple-negative breast cancer
    1. By Value
  5. Inflammatory breast cancer
    1. By Value
  6. Others
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Clinical Breast Exam
    1. By Value
  3. Blood Tests
    1. By Value
  4. Imaging Tests
    1. By Value
    2. Mammogram
      1. Mammogram By Value
    3. MRI
      1. MRI By Value
    4. Ultrasound
      1. Ultrasound By Value
    5. PET
      1. PET By Value
    6. Others
      1. Others By Value
  5. Biopsies
    1. By Value
    2. Excisional biopsy
      1. Excisional biopsy By Value
    3. Incisional biopsy
      1. Incisional biopsy By Value
    4. Core biopsy
      1. Core biopsy By Value
    5. Fine-needle aspiration (FNA) biopsy
      1. Fine-needle aspiration (FNA) biopsy By Value
    6. Others
      1. Others By Value
  6. Others
    1. By Value
3. By Stage
  1. Introduction
    1. Stage By Value
  2. Stage I
    1. By Value
  3. Stage II
    1. By Value
  4. Stage III
    1. By Value
  5. Stage IV
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Cancer Diagnostic Centers
    1. By Value
  4. Cancer Research Institutes
    1. By Value
  5. Ambulatory Surgical Centers
    1. By Value
  6. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Invasive lobular breast cancer
  1. By Value
3. Ductal carcinoma in situ (DCIS)
  1. By Value
4. Triple-negative breast cancer
  1. By Value
5. Inflammatory breast cancer
  1. By Value
6. Others
  1. By Value
By Test Type
1. Introduction
  1. Test Type By Value
2. Clinical Breast Exam
  1. By Value
3. Blood Tests
  1. By Value
4. Imaging Tests
  1. By Value
  2. Mammogram
    1. Mammogram By Value
  3. MRI
    1. MRI By Value
  4. Ultrasound
    1. Ultrasound By Value
  5. PET
    1. PET By Value
  6. Others
    1. Others By Value
5. Biopsies
  1. By Value
  2. Excisional biopsy
    1. Excisional biopsy By Value
  3. Incisional biopsy
    1. Incisional biopsy By Value
  4. Core biopsy
    1. Core biopsy By Value
  5. Fine-needle aspiration (FNA) biopsy
    1. Fine-needle aspiration (FNA) biopsy By Value
  6. Others
    1. Others By Value
6. Others
  1. By Value
By Stage
1. Introduction
  1. Stage By Value
2. Stage I
  1. By Value
3. Stage II
  1. By Value
4. Stage III
  1. By Value
5. Stage IV
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals and Clinics
  1. By Value
3. Cancer Diagnostic Centers
  1. By Value
4. Cancer Research Institutes
  1. By Value
5. Ambulatory Surgical Centers
  1. By Value
6. Others
  1. By Value
Brazil
1. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Invasive lobular breast cancer
    1. By Value
  3. Ductal carcinoma in situ (DCIS)
    1. By Value
  4. Triple-negative breast cancer
    1. By Value
  5. Inflammatory breast cancer
    1. By Value
  6. Others
    1. By Value
2. By Test Type
  1. Introduction
    1. Test Type By Value
  2. Clinical Breast Exam
    1. By Value
  3. Blood Tests
    1. By Value
  4. Imaging Tests
    1. By Value
    2. Mammogram
      1. Mammogram By Value
    3. MRI
      1. MRI By Value
    4. Ultrasound
      1. Ultrasound By Value
    5. PET
      1. PET By Value
    6. Others
      1. Others By Value
  5. Biopsies
    1. By Value
    2. Excisional biopsy
      1. Excisional biopsy By Value
    3. Incisional biopsy
      1. Incisional biopsy By Value
    4. Core biopsy
      1. Core biopsy By Value
    5. Fine-needle aspiration (FNA) biopsy
      1. Fine-needle aspiration (FNA) biopsy By Value
    6. Others
      1. Others By Value
  6. Others
    1. By Value
3. By Stage
  1. Introduction
    1. Stage By Value
  2. Stage I
    1. By Value
  3. Stage II
    1. By Value
  4. Stage III
    1. By Value
  5. Stage IV
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals and Clinics
    1. By Value
  3. Cancer Diagnostic Centers
    1. By Value
  4. Cancer Research Institutes
    1. By Value
  5. Ambulatory Surgical Centers
    1. By Value
  6. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Breast Cancer Diagnostics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Siemens Healthineers AG
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Kheiron Medical Technologies
Bio-Rad Laboratories
Hologic, Inc.
Koninklijke Philips N.V.
Quest Diagnostics Incorporated
FUJIFILM Holdings Corporation
GE Healthcare
Illumina, Inc.
Metaltronica SpA
Carestream Health

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment